Epameinondas Dogeas1, John L Cameron2, Cristopher L Wolfgang2, Kenzo Hirose2, Ralph H Hruban3, Martin A Makary2, Timothy A Pawlik4, Michael A Choti5. 1. Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9031, USA. 2. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Surgery, Ohio State University Wexner Medical Center, Columbus, OH, USA. 5. Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9031, USA. michael.choti@utsouthwestern.edu.
Abstract
BACKGROUND: Unlike other neuroendocrine tumors of the gastrointestinal tract, management of duodenal and periampullary carcinoids remains controversial. We aimed to determine the metastatic potential and optimal choice of therapy for these neoplasms. METHODS: A retrospective review of all patients treated at the Johns Hopkins Hospital between 1996 and 2012 was conducted. Clinicopathologic factors associated with lymph nodal involvement and clinical outcomes were evaluated. RESULTS: A total of 101 patients were identified. Eighty (79.2%) tumors arose from the duodenum and 21 (20.8%) from the periampullary area. Thirty-five (34.7%) patients underwent pancreaticoduodenectomy (PD), 12 (11.9%) local resection, 38 (37.6%) endoscopic excision, and 16 (15.8%) patients harbored incidental tumors identified in the specimen after PD for another indication. Lymph node (LN) pathologic evaluation was done in 56 patients, among which 27 (48%) had positive LN. Specifically, LN positivity (LN+) for tumors <1 cm in size was 4.5% (1/22), for tumors 1-2 cm 72% (13/18), and for tumors >2 cm 81% (13/16). Tumor size was the only factor associated with LN+ (p = 0.029). CONCLUSION: Lymph nodal involvement is common for duodenal and periampullary carcinoid tumors, particularly among those >1 cm in size; therefore, resection with lymphadenectomyfor these larger tumors is recommended.
BACKGROUND: Unlike other neuroendocrine tumors of the gastrointestinal tract, management of duodenal and periampullary carcinoids remains controversial. We aimed to determine the metastatic potential and optimal choice of therapy for these neoplasms. METHODS: A retrospective review of all patients treated at the Johns Hopkins Hospital between 1996 and 2012 was conducted. Clinicopathologic factors associated with lymph nodal involvement and clinical outcomes were evaluated. RESULTS: A total of 101 patients were identified. Eighty (79.2%) tumors arose from the duodenum and 21 (20.8%) from the periampullary area. Thirty-five (34.7%) patients underwent pancreaticoduodenectomy (PD), 12 (11.9%) local resection, 38 (37.6%) endoscopic excision, and 16 (15.8%) patients harbored incidental tumors identified in the specimen after PD for another indication. Lymph node (LN) pathologic evaluation was done in 56 patients, among which 27 (48%) had positive LN. Specifically, LN positivity (LN+) for tumors <1 cm in size was 4.5% (1/22), for tumors 1-2 cm 72% (13/18), and for tumors >2 cm 81% (13/16). Tumor size was the only factor associated with LN+ (p = 0.029). CONCLUSION:Lymph nodal involvement is common for duodenal and periampullary carcinoid tumors, particularly among those >1 cm in size; therefore, resection with lymphadenectomyfor these larger tumors is recommended.
Authors: John T Mullen; Huamin Wang; James C Yao; Jeffrey H Lee; Nancy D Perrier; Peter W T Pisters; Jeffrey E Lee; Douglas B Evans Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: Matthew H Kulke; Manisha H Shah; Al B Benson; Emily Bergsland; Jordan D Berlin; Lawrence S Blaszkowsky; Lyska Emerson; Paul F Engstrom; Paul Fanta; Thomas Giordano; Whitney S Goldner; Thorvardur R Halfdanarson; Martin J Heslin; Fouad Kandeel; Pamela L Kunz; Boris W Kuvshinoff; Christopher Lieu; Jeffrey F Moley; Gitonga Munene; Venu G Pillarisetty; Leonard Saltz; Julie Ann Sosa; Jonathan R Strosberg; Jean-Nicolas Vauthey; Christopher Wolfgang; James C Yao; Jennifer Burns; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2015-01 Impact factor: 11.908
Authors: Ganesh K Boora; Rahul Kanwar; Amit A Kulkarni; Josef Pleticha; Matthew Ames; Gary Schroth; Andreas S Beutler; Michaela S Banck Journal: Cancer Genet Date: 2015-04-14
Authors: Adriana C Gamboa; Yuan Liu; Rachel M Lee; Mohammad Y Zaidi; Charles A Staley; Maria C Russell; Kenneth Cardona; Patrick S Sullivan; Shishir K Maithel Journal: J Surg Oncol Date: 2019-08-26 Impact factor: 3.454
Authors: Catherine G Tran; Scott K Sherman; Mohammed O Suraju; Apoorve Nayyar; Henning Gerke; Rami G El Abiad; Chandrikha Chandrasekharan; Po Hien Ear; Thomas M O'Dorisio; Joseph S Dillon; Andrew M Bellizzi; James R Howe Journal: Ann Surg Oncol Date: 2021-09-13 Impact factor: 5.344
Authors: Adriana C Gamboa; Yuan Liu; Rachel M Lee; Mohammad Y Zaidi; Charles A Staley; David A Kooby; Joshua H Winer; Mihir M Shah; Maria C Russell; Kenneth Cardona; Shishir K Maithel Journal: J Surg Oncol Date: 2019-10-16 Impact factor: 3.454
Authors: R E Rossi; A C Milanetto; V Andreasi; D Campana; J Coppa; G Nappo; M Rinzivillo; P Invernizzi; R Modica; A David; S Partelli; G Lamberti; V Mazzaferro; A Zerbi; F Panzuto; C Pasquali; M Falconi; S Massironi Journal: J Endocrinol Invest Date: 2021-03-02 Impact factor: 4.256